Evidence map›Paper›PMID 40406337›Full record

ArticleJournal of Indian Association of Pediatric Surgeons

Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial.

Sunita Singh, Niraj Kumar Srivastava, Amrita Upadhyaya, Mrityunjay Kumar, Neeraj Pawar, Rohit Kapoor

Abstract read
In one paragraph

Article in Journal of Indian Association of Pediatric Surgeons. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sunita SinghDepartment of Paediatric Surgery, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.
Niraj Kumar SrivastavaDepartment of General Surgery, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.
Amrita UpadhyayaDepartment of Dermatology, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.
Mrityunjay KumarDepartment of Paediatrics, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.
Neeraj PawarDepartment of Community and Family Medicine, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.
Rohit KapoorDepartment of Paediatric Surgery, All India Institute of Medical Sciences, Raebareli, Uttar Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: To compare the efficacy of two topical agents in superficial infantile hemangioma (SIH). Materials and Methods: A Randomised controlled trial was carried out with details as follows. Design: A prospective double-blinded, double-armed, randomized controlled trial. Setting: Multidisciplinary unit from 2022 to 2024. Subjects: Children younger than 2 years with color Doppler-confirmed SIH (superficial to deep dermal fascia). Methods: Randomization in treatment arm I: topical beta-blocker 0.5% timolol maleate (TTM) solution or treatment arm II: ultrapotent topical Steroid 0.05% clobetasol propionate ointment. Outcome: (1) reduction in area, (2) color change on visual analog scale (VAS), and (3) total VAS scores for color, size, and thickness. Each VAS parameter was rated from 0 to 3 (cumulative score 0-9). Results: Twenty patients were enrolled in each arm. Four patients in each group missed 96 weeks of follow up assessment but completed at least 9 months of treatment. In arm I, two patients were transitioned from TTM to oral propranolol due to rapid progression deep into the dermis. Arm I demonstrated a quicker improvement in color with a steeper reduction in area. The mean total VAS score on 9-point sales was comparable in both arms at 3 months, 6 months, 12 months, 18 months, and 24 months of treatment ( Conclusion: 0.5%-TTM solution can be a first-line therapy for SIH due to its rapid onset of action and overall comparable efficacy in reducing SIH size. While clobetasol remains effective, its slower response may limit its utility.

Indexed as

0.05% clobetasol propionate0.5% timolol maleatebenign vascular tumorhemangiomainfantile hemangiomasuperficial infantile hemangiomatopical steroidvascular malformation

Identifiers

PMID40406337
PMCPMC12094592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.